Real World Evidence – Data for health

Real World Evidence (RWE) provides you with strategic support throughout the entire lifespan of medical products. With our solid expertise in RWE studies, we offer valuable information and services for successful progress from clinical phases to the post-marketing phase IV.

Oriola provides these services:

  • Our team of experienced specialists offers a wide range of services, including feasibility studies, patient surveys, drug utilization studies, and phase IV studies.
  • Leverage our unique digital platform for patient-reported outcomes, ensuring GDPR-compliant data usage and transparent medical research.
  • Combine Real World Data (RWD) from national registers and hospital data lakes with Patient Reported Outcomes (PRO) for a comprehensive view.
  • Gain insights into disease burden by incorporating patients' perspectives with national health register data.
  • We offer market research, landscape analyses, and data for health economic models to support market entry and pricing board decisions.

Nordic countries offer excellent conditions for register studies

Nordic countries provide ideal conditions for register studies, with similar laws, electronic data collection, and nation-wide cohort creation. 

Way to success: RWD + PRO = RWE

  • RWD (Real World Data): Collected from national registers, hospital data-lakes including various electronic medical records, and private healthcare providers.
  • PRO (Patient Reported Outcomes): Data collected through Oriola’s Research Pharmacy Network (around 150 active pharmacies in Finland), patient organisations and private healthcare providers.
  • RWD + PRO = RWE: Comprehensive picture of disease burden by combining patients’ perspective to national health register data

Contact us

Do not hesitate to contact us – we are ready to plan a tailored project just for your needs!

Tuire Prami

Tuire Prami

Real World Evidence Team Lead +358 50 546 8459

Interested in our other services?

You find them and relevant contact details here.